



PROF. ALESSANDRO MANTOVANI (6/1/1985), MD, PHD

PERSONAL INFORMATION

Name	MANTOVANI, Alessandro
Address	VIALE LUIGI RIZZARDI, 4 37022 NEGRAR DI VALPOLICELLA (VR), VERONA, ITALY
Telephone	045/6013713 Mobile +39/3403047101
Fax	None
E-mail	alessandro.mantovani@univr.it
URL for web site	https://www.dm.univr.it/?ent=persona&id=19414
Nationality	ITALIAN
Date of Birth	06 JANUARY 1985
Gender	MALE

WORK EXPERIENCE

FROM 2025 TO ONGOING

Metabolic Research Unit, IRCCS Sacro Cuore - Don Calabria,
Negrar di Valpolicella (VR), Italy
Department of Medicine, University of Verona, Italy

FROM 2023 TO 2025

Associate Professor in Endocrinology and Metabolic Diseases
Division of Endocrinology, Diabetes and Metabolism
Department of Medicine, University of Verona, Italy

FROM 2020 TO 2022

University Senior Researcher in Endocrinology, Assistant Professor in Endocrinology (RTDB)
Division of Endocrinology, Diabetes and Metabolism
Department of Medicine, University of Verona, Italy

From 2018 to 2022

Member of the Scientific Commission of the Italian Diabetes Society (SID)

From 2016 to 2020

Consultant in Endocrinology and Diabetology
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine
University and Azienda Ospedaliera Universitaria Integrata, Verona, Italy

From 2013 to 2016

University and Azienda Ospedaliera Universitaria Integrata, Verona, Italy
*Sub-investigator in Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (**DECLARE-TIMI 58**)*

EDUCATION AND TRAINING

From 2004 to 2010

UNIVERSITY OF VERONA, FACULTY OF MEDICINE AND SURGERY
Degree in Medicine and Surgery, MEDICAL DOCTOR

From 2011 to 2016

UNIVERSITY OF VERONA, FACULTY OF MEDICINE AND SURGERY,
SPECIALIZATION IN ENDOCRINOLOGY AND DIABETOLOGY

From 2016 to 2020

UNIVERSITY OF VERONA, ITALY
Degree of Physician Doctorate (Ph.D.) in "Sperimental and Clinical Biomedical Science"

From 2018 to 2027

National Scientific qualification as associate in the Italian higher education system, in the call 2016/2018 (Ministerial Decree n. 1532/2016) for the disciplinary field of 06/D2 - Endocrinology, nephrology, food and wellness science. (Academic Recruitment Field 06/D - Medical specialities, according to the national classification). The validity of the qualification is nine years, starting from the 21/09/2018 and will expire on the 21/09/2027.

From 2025 to 2037

National Scientific qualification as full professor in the Italian higher education system, in the call 2016/2018 (Ministerial Decree n. 1532/2016) for the disciplinary field of 06/D2 - Endocrinology, nephrology, food and wellness science. (Academic Recruitment Field 06/D - Medical specialities, according to the national classification). The validity of the qualification starting from the 14/03/2025 and will expire on the 14/03/2037

TEACHING ACTIVITY

To: University of Verona:

- Master's degree in Preventive and Adapted Exercise Science (2023-ongoing)
- Master's degree in Sport Science and Physical Performance (2023-ongoing)
- Bachelor's degree in Nursing (to qualify as a nurse) (2020-ongoing)
- Doctoral Program (Ph.D.) in "Sperimental and Clinical Biomedical Sciences" (2020 - ongoing)
- Combined Bachelor's + Master's degree in Medicine and Surgery - Systematic pathology II (2020-ongoing)
- Specialization School in Endocrinology and Diabetology (2020 - ongoing)

Please see: <https://www.dm.univr.it/?ent=persona&id=19414>

PERSONAL SKILLS AND COMPETENCES

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.

FIRST LANGUAGE

ITALIAN

OTHERS

• READING
• WRITING
• SPEACHING

SCIENTIFIC SKILLS
AND COMPETENCES

ENGLISH

GOOD
GOOD
GOOD

Scopus Author ID: 57200609626
RESEARCHERID: AAB-9015-2019
ORCID: <http://orcid.org/0000-0002-7271-6329>
<http://www.webofscience.com/wos/author/record/AAB-9015-2019>

Total citations: 8746

h-index: 50

(source: Scopus, **updated to 2 February 2025**)

PUBLICATIONS (updated to 09 September 2025)

1. **Mantovani A**, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. *J Endocrinol Invest* 2012; 35: 215-8. doi: 10.1007/BF03345421.
2. Targher G, Zoppini G, Mantovani W, Chonchol M, Negri C, Stoico V, **Mantovani A**, De Santi F, Bonora E. Comparison of two creatinine-based estimating equations in predicting all-cause and cardiovascular mortality in patients with type 2 diabetes. *Diabetes Care* 2012; 35: 2347-53. doi: 10.2337/dc12-0259. Epub 2012 Jul 26.
3. Targher G, **Mantovani A**, Pichiri I, Rigolon R, Dauriz M, Zoppini G, Morani G, Vassanelli C, Bonora E. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. *Clin Sci (Lond)* 2013;125: 301-9. doi: 10.1042/CS20130036.
4. Targher G, Scorletti E, **Mantovani A**, Byrne CD. Nonalcoholic fatty liver disease and reduced serum vitamin D(3) levels. *Metab Syndr Relat Disord* 2013; 11: 217-28. doi: 10.1089/met.2013.0044.
5. Bonapace S, Valbusa F, Bertolini L, Pichiri I, **Mantovani A**, Rossi A, Zenari L, Barbieri E, Targher G. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. *PLoS One* 2014; 9: e88371. doi: 10.1371/journal.pone.0088371
6. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Pichiri I, **Mantovani A**, Zoppini G, Bonora E, Barbieri E, Byrne CD. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. *Nutr Metab Cardiovasc Dis* 2014; 24: 663-9. doi: 10.1016/j.numecd.2014.01.005.
7. Targher G, **Mantovani A**, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, Pancheri S, Trombetta M, Zoppini G, Chonchol M, Byrne CD, Bonora E. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. *Diabetes Care* 2014; 37: 1729-36. doi: 10.2337/dc13-2704.
8. **Mantovani A**, Pernigo M, Bergamini C, Bonapace S, Lipari P, Valbusa F, Bertolini L, Zenari L, Pichiri I, Dauriz M, Zoppini G, Barbieri E, Byrne CD,

- Bonora E, Targher G. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Metabolism* 2015; 64: 879-887. doi: 10.1016/j.metabol.2015.04.003.
9. **Mantovani A**, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, Bertolini L, Valbusa F, Barbieri E, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. *PLoS One* 2015; 10: e0135329. doi: 10.1371/journal.pone.0135329
 10. Bonapace S, Rossi A, Lipari P, Bertolini L, Zenari L, Lanzoni L, Canali G, Molon G, **Mantovani A**, Zoppini G, Bonora E, Barbieri E, Targher G. Relationship between increased left atrial volume and microvascular complications in patients with type 2 diabetes. *J Diabetes Complications*. 2015; 29: 822-8. doi: 10.1016/j.jdiacomp.2015.05.006.
 11. **Mantovani A**, Rigolon R, Pichiri I, Pernigo M, Bergamini C, Zoppini G, Bonora E, Targher G. Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. *J Endocrinol Invest* 2016; 39: 159-67. doi: 10.1007/s40618-015-0354-z.
 12. **Mantovani A**, Ballestri S, Lonardo A, Targher G. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. *Dig Dis Sci* 2016; 61: 1246-1267. doi: 10.1007/s10620-016-4040-6
 13. **Mantovani A**, Gisondi P, Lonardo A, Targher G. Relationship Between Non-Alcoholic Fatty Liver Disease and Chronic Plaque Psoriasis: A Novel Hepato-Dermal Axis? *Int J Mol Sci* 2016 Feb 5;17(2):217. doi: 10.3390/ijms17020217.
 14. **Mantovani A**, Trombetta M, Imbriaco C, Rigolon R, Mingolla L, Zamboni F, Dal Molin F, Cioccoloni D, Sanga V, Bruti M, Brocco E, Conti M, Ravenna G, Perrone F, Stoico V, Bonora E. Diabetic Foot Complicated By Vertebral Osteomyelitis And Epidural Abscess: A Case Report. *Endocrinology, Diabetes and Metabolism Case Reports* 2016, 15-0132; May 2016; DOI: 10.1530/EDM-15-0132.
 15. **Mantovani A**, Rigamonti A, Bonapace S, Bolzan B, Pernigo M, Morani M, Franceschini L, Bergamini C, Bertolini L, Valbusa F, Rigolon R, Pichiri I, Zoppini G, Bonora E, Violi F, Targher G. Non-alcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias In Patients With Type 2 Diabetes Referred For Clinically Indicated 24-hour Holter Monitoring. *Diabetes Care* 2016; 39: 1416-1423. doi: 10.2337/dc16-0091.
 16. **Mantovani A**, Grani G, Chioma L, Vancieri G, Giordani I, Rendina R, Rinaldi ME, Andreadi A, Coccaro C, Boccardo C, Fraenza C, Bertazzoni G, Bellia A, Zoppini G, Targher G, Baroni MG, Lauro D, D'Armiento M, Bonora E. Severe Hypoglycemia In Patients With Known Diabetes Requiring Emergency Department Care: A Report From An Italian Multicenter Study. *Journal of Clinical & Translational Endocrinology* 2016; 5: 46-52. doi: 10.1016/j.jcte.2016.08.004
 17. **Mantovani A**, Mingolla L, Rigolon R, Pichiri I, Cavaliere V, Zoppini G, Lippi G, Bonora E, Targher G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. *International Journal of Cardiology* 2016; 225: 387-391. doi: 10.1016/j.ijcard.2016.10.040

18. Bonapace S, Valbusa F, Bertolini L, Zenari L, Canali G, Molon G, Lanzoni L, Cecchetto A, Rossi A, **Mantovani A**, Zoppini G, Barbieri E, Targher G. Early Impairment in Left Ventricular Longitudinal Systolic Function Is Associated With An Increased Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes. *J Diabetes Complications* 2017; 31: 413-418. doi: 10.1016/j.jdiacomp.2016.10.032.
19. Zoppini G, Bergamini C, Toffalini A, Bonapace S, Rossi A, Trombetta M, **Mantovani A**, Lanzoni L, Bertolini L, Zenari L, Bonora E, Targher G. Association between subclinical left ventricular systolic dysfunction and glycemic control in asymptomatic type 2 diabetic patients with preserved left ventricular function. *J Diabetes Complications* 2017; 31: 1035-1040. doi: 10.1016/j.jdiacomp.2017.01.021
20. **Mantovani A**, Rigolon R, Mingolla L, Pichiri I, Cavalieri V, Salvotelli L, Stoico V, Zoppini G, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease Is Associated With An Increased Prevalence of Distal Symmetric Polyneuropathy In Adult Patients With Type 1 Diabetes. *J Diabetes Complications* 2017; 31: 1021-1026. doi: 10.1016/j.jdiacomp.2017.01.024.
21. Valbusa F, Bonapace S, Agnoletti D, Scala L, Grillo C, Arduini P, Turcato E, **Mantovani A**, Zoppini G, Arcaro G, Byrne C, Targher G. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. *PLoS One* 2017; 12: e0173398. doi: 10.1371/journal.pone.0173398.
22. **Mantovani A**, Targher G. Type 2 Diabetes Mellitus And Risk Of Hepatocellular Carcinoma: Spotlight On Nonalcoholic Fatty Liver Disease. *Annals of Translational Medicine*, 2017; 5 (13): 270. doi: 10.21037/atm.2017.04.41.
23. **Mantovani A**. Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis. *J Clin Transl Hepatol* 2017; 5: 134-141. doi: 10.14218/JCTH.2017.00005.
24. **Mantovani A**, Perrone F, Stoico V, Pichiri I, Salvotelli L, Teobaldi I, Bruti M, Conti M, Cima L, Eccher A, Bonora E. Primary Cutaneous B-Cell Lymphoma And Chronic Leg Ulcers In A Patient With Type 2 Diabetes: A Case Report. *Endocrinology, Diabetes and Metabolism Case Reports* 2017, 17-0032; DOI: 10.1530/EDM-17-0032.
25. **Mantovani A**, Rigolon R, Civettini A, Bolzan B, Morani G, Bonapace S, Dugo C, Zoppini G, Bonora E, Targher G. Hyperuricemia is Associated With an Increased Prevalence of Paroxysmal Atrial Fibrillation in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. *Journal of Endocrinological Investigation* 2018; 41: 223-231. doi: 10.1007/s40618-017-0729-4.
26. Dauriz M, **Mantovani A**, Bonapace S, Verlato G, Zoppini G, Bonora E, Targher G. Prognostic impact of diabetes mellitus on long-term survival outcomes in patients with heart failure. A meta-analysis. *Diabetes Care* 2017; 40: 1597-1605. doi: 10.2337/dc17-0697.
27. Lonardo A, Nascimbeni F, **Mantovani A**, Targher G. Hypertension, Diabetes, Atherosclerosis and NASH: Cause Consequence? *J Hepatol* 2018; 68: 335-352. doi: 10.1016/j.jhep.2017.09.021.
28. **Mantovani A**, Rigolon R, Pichiri I, Bonapace S, Morani G, Zoppini G, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease Is Associated With An Increased

Risk of Heart Block in Hospitalized Patients With Type 2 Diabetes Mellitus. PLoS ONE 2017; 12(10): e0185459. doi: 10.1371/journal.pone.0185459.

29. **Mantovani A**, Rigolon R, Pichiri I, Morani G, Bonapace S, Dugo C, Zoppini G, Bonora E, Targher G. Relation of Elevated Serum Uric Acid Levels to First-degree Heart Block and Other Cardiac Conduction Defects in Hospitalized Patients with Type 2 Diabetes. J Diabetes Complications 2017, 31: 1691-1697. doi: 10.1016/j.jdiacomp.2017.09.011.
30. **Mantovani A**, Caimmi C, Orsolini G. Cardiovascular Morbidity And Mortality In Patients With Rheumatic Disease: Hyperuricemia, A Forgotten Puzzle Piece? Clin Rheumatol 2017; 36: 2869-2870. doi: 10.1007/s10067-017-3881-5.
31. **Mantovani A**, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease Increases Risk of Incident Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Metabolism 2018; 79: 64-76. doi: 10.1016/j.metabol.2017.11.003.
32. **Mantovani A**, Byrne CD, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes Mellitus: A Meta-Analysis. Diabetes Care 2018 Feb;41(2):372-382. doi: 10.2337/dc17-1902.
33. Nascimbeni F, Ballestri S, Machado MV, **Mantovani A**, Cortez-Pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histologic classifications of NASH in adults. Expert Rev Gastroenterol Hepatol 2018; 12: 351-367. doi: 10.1080/17474124.2018.1415756.
34. Anstee QM, **Mantovani A**, Tilg H, Targher G. Risk of Cardiomyopathy And Cardiac Arrhythmias In Patients With Non-Alcoholic Fatty Liver Disease. Nat Rev Gastroenterol Hepatol 2018;15: 425-439. doi: 10.1038/s41575-018-0010-0.
35. **Mantovani A**. NAFLD And Risk of Cardiac Arrhythmias: Is Hyperuricemia A Neglected Pathogenic Mechanism? Dig Liver Dis 2018; 50: 518-520. doi: 10.1016/j.dld.2018.02.002.
36. Teobaldi I, **Mantovani A**. Pressure Heel Ulcers In Patient With Type 2 Diabetes: Is It T.I.M.E. To Customize The Wound Bed Preparation According To Different Heel Areas? International Wound Journal 2018, Apr 17. doi: 10.1111/iwj.12914.
37. **Mantovani A**, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Prognostic Impact of Elevated Serum Uric Acid Levels on Long-Term Outcomes in Patients with Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. Metabolism 2018; 83: 205-215. doi: 10.1016/j.metabol.2018.02.007.
38. **Mantovani A**, Nascimbeni F. Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation? Dig Liver Dis 2018; 50: 626-628. doi: 10.1016/j.dld.2018.03.012.
39. **Mantovani A**, Grani G. Thyroid dysfunction and non-alcoholic fatty liver disease: we need new larger and well-designed longitudinal studies. Dig Dis Sci 2018; 63: 1970-1976. doi: 10.1007/s10620-018-5075-7

40. Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, Calabria S, Scaturro G, **Mantovani A**, Zoppini G, Turcato M, Maggioni AP, Arcaro G, Targher G. Non-alcoholic Fatty Liver Disease and Increased Risk of All-Cause Mortality in Elderly Patients Admitted for Acute Heart Failure. *Int J Cardiol* 2018; 265: 162-168. doi: 10.1016/j.ijcard.2018.04.129.
41. **Mantovani A**, Bonapace S, Lunardi G, Salgarello M, Dugo C, Canali G, Byrne CD, Gori S, Barbieri E, Targher G. Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. *Metabolism* 2018; 85: 305-312. doi: 10.1016/j.metabol.2018.05.006.
42. Zoppini G, Bergamini C, Bonapace S, Trombetta M, **Mantovani A**, Toffalini A, Lanzoni L, Bertolini L, Zenari L, Bonora E, Targher G, Rossi A. Left ventricular chamber dilation and filling pressure may help to categorize patients with type 2 diabetes. *BMJ Open Diabetes Research and Care* 2018; 6: e000529. doi: 10.1136/bmjdr-2018-000529.
43. **Mantovani A**, Dauriz M, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Association Between Nonalcoholic Fatty Liver Disease and Colorectal Tumours in Asymptomatic Adults Undergoing Screening Colonoscopy: A Systematic Review and Meta-Analysis. *Metabolism* 2018; 87:1-12. doi: 10.1016/j.metabol.2018.06.004
44. Lever V, Erdini F, Ghimenton C, Novelli L, Brunelli M, Barbareschi M, Mazzoleni G, Vermiglio E, **Mantovani A**, Cima L, Valotto G, Eccher A. Coronary Fat Embolism and Coronary Amyloidosis. *Am J Case Rep* 2018; 19: 744-747. doi: 10.12659/AJCR.908561.
45. **Mantovani A**, Teobaldi I, Stoico V, Perrone F, Zannoni Marina, Cima L, Bruti M, Mingolla L, Trombetta M, Bonora E. Squamous Carcinoma In A Patient With Diabetic Foot: An Unusual Evolution of A Frequent Complication. *Endocrinol Diabetes Metab Case Rep.* 2018 Jul 31;2018. pii: 18-0065. doi: 10.1530/EDM-18-0065.
46. **Mantovani A**. Plasma trans-fatty acid and risk of nonalcoholic fatty liver disease: New data from National Health and Nutrition Examination Survey (NHANES). *Int J Cardiol* 2018; 272: 329-330. doi: 10.1016/j.ijcard.2018.07.136
47. **Mantovani A**, Nascimbeni F, Lonardo A, Zoppini G, Bonora E, Mantzoros C, Targher G. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Thyroid* 2018; 28: 1270-1284. doi: 10.1089/thy.2018.0257
48. **Mantovani A**, Rigolon R, Turino T, Pichiri I, Falceri A, Rossi A, Temporelli PL, Bonapace S, Lippi G, Zoppini G, Bonora E, Byrne CD, Targher G. Association between decreasing estimated glomerular filtration rate and risk of cardiac conduction defects in patients with type 2 diabetes. *Diabetes Metab* 2018; 44: 473-481. doi: 10.1016/j.diabet.2018.08.007.
49. **Mantovani A**, Sani E, Gatti D, Colecchia A, Amato E, Fassio A, Idolazzi L, Rossini M, Salvagno G, Lippi G, Zoppini G, Byrne CD, Bonora E, Targher G. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. *Diabetes Metab.* 2019; 45: 347-355. doi: 10.1016/j.diabet.2018.10.001.
50. **Mantovani A**, Bonapace S, Lunardi G, Salgarello M, Dugo C, Gori S, Barbieri E, Verlato G, Laaksonen R, Byrne CD, Targher G. Association of plasma

ceramides with myocardial perfusion in patients with coronary artery disease undergoing stress myocardial perfusion scintigraphy. *Arterioscler Thromb Vasc Biol* 2018; 38: 2854-2861. doi: 10.1161/ATVBAHA.118.311927.

51. **Mantovani A.** Not all NAFLD patients are the same: we need to find a personalized therapeutic approach. *Dig Liver Dis* 2019; 51: 176-177. doi: 10.1016/j.dld.2018.10.009
52. Lugari S, **Mantovani A**, Nascimbeni F, Lonardo A. Hypothyroidism and nonalcoholic fatty liver disease - a chance association? *Horm Mol Biol Clin Investig.* 2018 Oct 26;41(1):/j/hmbci.2020.41.issue-1/hmbci-2018-0047/hmbci-2018-0047.xml. doi: 10.1515/hmbci-2018-0047.
53. **Mantovani A.** Nonalcoholic Fatty Liver Disease and Bone Mineral Density in Children and Adolescents: Specific Considerations for Future Studies. *Dig Dis Sci* 2019; 64: 898-900. doi: 10.1007/s10620-018-5370-3.
54. Teobaldi I, Stoico V, Perrone F, Bruti M, Bonora E, **Mantovani A.** Honey dressing on a leg ulcer with tendon exposure in a patient with type 2 diabetes. *Endocrinology, Diabetes and Metabolism Case Reports* 2018, 18-0117; DOI: 10.1530/EDM-18-0117.
55. **Mantovani A.** Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes. *Liver Int.* 2019; 39: 779. doi: 10.1111/liv.14019.
56. **Mantovani A.** Time to Revise the definition of NAFLD: A purist vision. *Dig Liver Dis.* 2019; 51: 457-458. doi: 10.1016/j.dld.2018.12.018.
57. Zoppini G, Bergamini C, **Mantovani A**, Dauriz M, Targher G, Rossi A, Bonora E. The E/e' ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies. *PLoS One* 2018; 13: e0209794. doi: 10.1371/journal.pone.0209794.
58. **Mantovani A**, Dauriz M, Gatti D, Viapiana O, Zoppini G, Lippi G, Byrne CD, Bonnet F, Bonora E, Targher G. Systematic review and meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. *Aliment Pharmacol Ther* 2019; 49: 375–388. doi: 10.1111/apt.15087.
59. **Mantovani A**, Sartori F. Gender difference in authorship of clinical practice guidelines and position statements in Endocrinology. *J Endocrinol Invest.* 2019; 42: 489-490. doi: 10.1007/s40618-019-1008-3.
60. **Mantovani A**, Dauriz M, Sandri D, Bonapace S, Zoppini G, Tilg H, Byrne CD, Targher G. Association between nonalcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. *Liver Int.* 2019; 39: 758-769. doi: 10.1111/liv.14044.
61. Targher G, **Mantovani A**, Dauriz M, Bonnet F, Byrne CD. *Letter:* non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density - authors' reply. *Aliment Pharmacol Ther* 2019; 49: 961-962. doi: 10.1111/apt.15181
62. **Mantovani A**, Gatti D, Zoppini G, Lippi G, Bonora E, Byrne CD, Nobili V, Targher G. Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. *Hepatology.* 2019 Sep;70(3):812-823. doi: 10.1002/hep.30538

63. **Mantovani A**, Zusi C, Sani E, Colecchia A, Lippi G, Zaza G, Valenti L, Byrne CD, Maffei C, Targher G. Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. *Diabetes Metab.* 2019 Oct;45(5):480-487. doi: 10.1016/j.diabet.2019.01.011.
64. Lonardo A, Ballestri S, **Mantovani A**, Nascimbeni F, Lugari S, Targher G. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? *Dig Liver Dis.* 2019; 51: 462-470. doi: 10.1016/j.dld.2018.12.014.
65. **Mantovani A**, Altomari A, Fassio A, Gatti D, Bonnet F, Targher G. Association Between Increased Carotid Intima-Media Thickness and Higher Serum C-Terminal Telopeptide of Type I Collagen Levels In Post-Menopausal Women With Type 2 Diabetes. *Diabetes Metab.* 2020 Oct;46(5):409-411. doi: 10.1016/j.diabet.2019.02.005.
66. Targher G, **Mantovani A**, Alisi A, Mosca A, Byrne CD, Nobili V. Relationship between PNPLA3 rs738409 polymorphism and decreased kidney function in children with NAFLD. *Hepatology.* 2019; 70: 142-153. doi: 10.1002/hep.30625.
67. Zoppini G, Bergamini C, Trombetta M, Sabbagh L, Dauriz M, **Mantovani A**, Targher G, Fossà I, Rinaldi E, Bonora E. Increased aortic stiffness index in patients with type 1 diabetes without cardiovascular disease compared to controls. *J Endocrinol Invest.* 2019; 42: 1109-1115. doi: 10.1007/s40618-019-01032-7.
68. **Mantovani A**, Nascimbeni F, Buzzetti E, Dalbeni A. Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements. *Dig Liver Dis.* 2019; 51: 911-913. doi: 10.1016/j.dld.2019.04.005.
69. **Mantovani A**, Turino T, Altomari A, Lonardo A, Zoppini G, Valenti L, Tilg H, Byrne CD, Targher G. Association Between Helicobacter Pylori Infection and Risk of Nonalcoholic Fatty Liver Disease: an Updated Meta-analysis. *Metabolism.* 2019; 96: 56-65. doi: 10.1016/j.metabol.2019.04.012.
70. **Mantovani A**, Lonardo A, Vinco G, Zoppini G, Lippi G, Bonora E, Lomboa R, Tilg H, Byrne CD, Fabbri L, Targher G. Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis. *Diabetes Metab* 2019 Dec;45(6):536-544. doi: 10.1016/j.diabet.2019.04.008
71. **Mantovani A**, Altomari A, Lunardi G, Boanpace S, Bonnet F, Targher G. Association between distinct plasma ceramides and high-sensitivity C-reactive protein levels in post-menopausal women with type 2 diabetes. *Diabetes and Metabolism* 2020 Sep;46(4):326-330. doi: 10.1016/j.diabet.2019.05.008.
72. Lonardo A, **Mantovani A**, Lugari S, Targher G. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. *Int J Mol Sci* 2019 Jun 11;20(11):2841. doi: 10.3390/ijms20112841.
73. Zusi C, **Mantovani A**, Olivieri F, Morandi A, Corradi M, Miraglia Del Giudice E, Dauriz M, Valenti L, Byrne CD, Targher G, Maffei C. Contribution of a genetic

- risk score to clinical prediction of hepatic steatosis in obese children and adolescents. *Dig Liver Dis.* 2019 Nov;51(11):1586-1592. doi: 10.1016/j.dld.2019.05.029.
74. Nobili V, **Mantovani A**, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffei C, Lomboa R, Byrne CD, Targher G. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven nonalcoholic fatty liver disease. *J Hepatol.* 2019; 71: 802-810. doi: 10.1016/j.jhep.2019.06.023.
 75. Zoppini G, Trombetta M, Sabbagh L, Dauriz M, **Mantovani A**, Bergamini C. Impaired Aortic Valve Growth in Type 1 Diabetes Mellitus. *Can J Cardiol* 2019 Jul;35(7):941.e5-941.e6. doi: 10.1016/j.cjca.2019.04.001
 76. Mosca A, Comparcola D, Romito I, **Mantovani A**, Nobili V, Byrne CD, Alisi A, Targher G. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. *Liver Int.* 2019; 39: 2317-2329. doi: 10.1111/liv.14225.
 77. Valbusa F, Angheben A, **Mantovani A**, Zerbato V, Chiampan A, Bonapace S, Rodari P, Agnoletti D, Arcaro G, Fava C, Bisoffi Z, Targher G. Increased aortic stiffness in adults with chronic indeterminate Chagas disease. *PLoS One* 2019; 14(8): e0220689. doi: 10.1371/journal.pone.0220689.
 78. **Mantovani A**, Bonapace S, Lunardi G, Canali G, Dugo C, Vinco G, Calabria S, Barbieri E, Laaksonen R, Bonnet F, Byrne CD, Targher G. Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. *Diabetes Metab.* 2020 Apr;46(2):150-157. doi: 10.1016/j.diabet.2019.07.006
 79. **Mantovani A**, Zusi C. Letter to the Editor about PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease? *Nutr Metab Cardiovasc Dis.* 2020 Jan 3;30(1):162-163. doi: 10.1016/j.numecd.2019.09.009.
 80. Ballestri S, **Mantovani A**, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. *Future Med Chem.* 2019; 11: 2171-2192. doi: 10.4155/fmc-2019-0003.
 81. **Mantovani A**, Zusi C. The Dawn Of A New Era For Nonalcoholic Fatty Liver Disease? *Hepatobiliary Surg Nutr.* 2019; 8: 629-631. doi: 10.21037/hbsn.2019.09.15.
 82. Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, **Mantovani A**, Maffei C, Colecchia A, Villani R, Rinaldi L, Orsi E, Pisano G, Adinolfi LE, Fargion S, Fracanzani AL. Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. *Liver Int.* 2020 Feb;40(2):347-354. doi: 10.1111/liv.14274.
 83. **Mantovani A**, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of kidney dysfunction in NAFLD. *Curr Pharm Des.* 2020;26(10):1045-1061. doi: 10.2174/1381612825666191026113119.
 84. **Mantovani A**, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, Ravaioli F, Colecchia A, Maffei C, Salvagno G, Lippi G, Bonora E, Targher G. Screening for nonalcoholic fatty liver disease with liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. *Diabetes Metab.* 2020 Sep;46(4):296-303. doi:

85. **Mantovani A**, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. *Diabetes Metab.* 2020 Nov;46(6):427-441. doi: 10.1016/j.diabet.2019.12.007.
86. **Mantovani A**, Dugo C. Ceramides and risk of major adverse cardiovascular events: A meta-analysis of longitudinal studies. *J Clin Lipidol.* 2020 Mar-Apr 2020;14(2):176-185. doi: 10.1016/j.jacl.2020.01.005.
87. **Mantovani A**, Zusi C, Rinaldi E, Bittante C, Ceruti V, Dalbeni A. Gender Differences In Editorial Boards of Journals in Hepatology. *Dig Liver Dis* 2020 Apr;52(4):469-470. doi: 10.1016/j.dld.2020.01.005.
88. **Mantovani A**, Rinaldi E, Zusi C. Gender Disparity In Editorial Boards of Scientific Journals in Endocrinology. *Journal of Endocrinological Investigation* 2020;43(4):549-550. doi: 10.1007/s40618-020-01190-z.
89. **Mantovani A**, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. *Metabolism.* 2020 Oct;111S:154170. doi: 10.1016/j.metabol.2020.154170.
90. **Mantovani A**, Zusi C. PNPLA3 gene and kidney disease *Explor Med.* 2020;1:42–50 DOI: <https://doi.org/10.37349/emed.2020.00004>.
91. **Mantovani A**, Taliento A, Zusi C, Baselli G, Prati D, Granata S, Zaza G, Colecchia A, Maffei C, Byrne CD, MB Valenti L, Targher G. PNPLA3 I148M gene variant and Chronic Kidney Disease in Type 2 Diabetic Patients With NAFLD: Clinical and Experimental Findings. *Liver Int.* 2020 May;40(5):1130-1141. doi: 10.1111/liv.14419.
92. Lonardo A, **Mantovani A**, Lunardi S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Ann Hepatol.* 2020 Jul-Aug;19(4):359-366. doi: 10.1016/j.aohep.2020.03.001.
93. **Mantovani A**, Dalbeni A, Beatrice G. Coronavirus disease 2019 (COVID-19): We don't leave women alone. *Int J Public Health.* 2020 Apr;65(3):235-236. doi: 10.1007/s00038-020-01369-4.
94. **Mantovani A**, Lunardi G, Bonapace S, Dugo C, Altomari A, Molon G, Conti A, Bovo C, Laaksonen R, Byrne CD, Bonnet F, Targher G. Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease. *Diabetes Metab.* 2021 Feb;47(1):101152. doi: 10.1016/j.diabet.2020.03.003.
95. **Mantovani A**, Beatrice G, Dalbeni A. Coronavirus disease 2019 (COVID-19) and prevalence of chronic liver disease: A meta-analysis. *Liver Int.* 2020;40:1316–1320. doi: 10.1111/liv.14465.
96. Bonora E, Dauriz M, Rinaldi E, **Mantovani A**, Boscari F, Mazzuccato M, Vedovato M, Gallo A, Toffanin E, Lapolla A, Fadini GP, Avogaro A. Assessment of simple strategies for identifying undiagnosed diabetes and prediabetes in the general population. *J Endocrinol Invest.* 2021 Jan;44(1):75-81. doi: 10.1007/s40618-020-01270-0.
97. **Mantovani A**, Beatrice G, Petracca G, Pampagni F, Sandri D, Targher G. GLP-1 Receptor Agonists For NAFLD Treatment In Patients With And Without Type

2 Diabetes: An Updated Meta-Analysis. *Explor Med.* 2020;1:108–123 DOI: <https://doi.org/10.37349/emed.2020.00008>.

98. Andreoli B, **Mantovani A**, Andreoli C. Type 2 Diabetes, sarcopenic obesity and Mediterranean food pattern: considerations about the therapeutic effect and the problem of maintaining weight loss and healthy habits. The outpatient experience of two clinical cases. *Journal of Clinical and Translational Endocrinology Case Reports* 2020; 16:100061. DOI: 10.1016/j.jecr.2020.100061.
99. Targher G, **Mantovani A**, Byrne CD, Wang XB, Yan HD, Sun QF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Risk of severe illness from COVID-19 in patients with metabolic associated fatty liver disease and increased fibrosis scores. *Gut* 2020 Aug;69(8):1545-1547. doi: 10.1136/gutjnl-2020-321611.
100. Targher G, **Mantovani A**, Wang XB, Yan HD, Sun QF, Byrne CD, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Patients with diabetes are at higher risk for severe illness from COVID-19. *Diabetes Metab.* 2020 Sep;46(4):335-337. doi: 10.1016/j.diabet.2020.05.001.
101. **Mantovani A**, Zheng MH, Byrne CD, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies. *Nutr Metab Cardiovasc Dis.* 2020 May 29;30(8):1236-48. doi: 10.1016/j.numecd.2020.05.014.
102. Targher G, **Mantovani A**, Byrne CD, Wang XB, Yan HD, Sun QF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Differential impacts of metabolic associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on risk of severe illness from COVID-19. *Diabetes Metab.* 2020 Nov;46(6):505-507. doi: 10.1016/j.diabet.2020.06.001.
103. Mariotto S, Carta S, Bozzetti S, Zivelonghi C, Alberti D, Zanzoni S, Filosto M, Fusina S, Monaco S, Castellani F, **Mantovani A**, Cavallaro T, Briani C, Ferrari S. Sural Nerve Biopsy: Current Role and Comparison With Serum Neurofilament Light Chain Levels. *J Neurol.* 2020 Oct;267(10):2881-2887. doi: 10.1007/s00415-020-09949-3.
104. **Mantovani A**, Rinaldi E, Zusi C, Beatrice G, Deganello Saccomani M, Dalbeni A. Coronavirus disease 2019 (COVID-19) In Children and/or Adolescents: A Meta-analysis. *Pediatr Res.* 2021 Mar;89(4):733-737. doi: 10.1038/s41390-020-1015-2.
105. **Mantovani A**, Danese E, Salvagno GL, Gelati M, Turino T, Bovo C, Lippi G, Targher G. Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. *J Endocrinol Invest.* 2021 Mar;44(3):547-555. doi: 10.1007/s40618-020-01340-3.
106. Mariotto S, Beatrice G, Carta S, Bozzetti S, **Mantovani A**. Gender Disparity In Editorial Boards of Journals in Neurology. *Neurology.* 2020 Sep 15;95(11):489-491. doi: 10.1212/WNL.0000000000010500.
107. Targher G, Lunardi G, **Mantovani A**, Meessen J, Bonapace S, Temporelli PT, Nicolis E, Novelli D, Conti A, Tavazzi L, Maggioni AP, Latini R, on behalf of the GISSI-HF Investigators. Relation between plasma ceramides and cardiovascular death in chronic heart failure: a subset analysis of the GISSI-HF trial. *ESC Heart Fail.* 2020 Jul 6;7(6):3288-3297. doi: 10.1002/ehf2.12885.
108. **Mantovani A**, Targher G, Zoppini G. Nonalcoholic Fatty Liver Disease and

Implications for Older Adults with Diabetes. Clin Geriatr Med. 2020;36(3):527-547. doi: 10.1016/j.cger.2020.04.010

109. Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, **Mantovani A**, Maffei C, Colecchia A, Villani R, Rinaldi L, Orsi E, Pisano G, Adinolfi LE, Fargion S, Fracanzani AL. NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. J Diabetes Complications. 2020;34(11):107684. doi: 10.1016/j.jdiacomp.2020.107684.
110. Bittante C, Beatrice G, Carletti L, **Mantovani A**. Gender disparity in authorships of manuscripts on the COVID-19 outbreak. Z Gesundh Wiss. 2020 Jun 5:1-2. doi: 10.1007/s10389-020-01323-x. Epub ahead of print. PMID: 32837838; PMCID: PMC727223.
111. **Mantovani A**, Rinaldi E, Zusi C. Country Rankings on The Scientific Production In Endocrinology And Diabetology. Explor Med. 2020;1:[Online First]. <https://doi.org/10.37349/emed.2020.00020>.
112. **Mantovani A**, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021 May;70(5):962-969. doi: 10.1136/gutjnl-2020-322572.
113. Fassio A, Adami G, Idolazzi L, Giollo A, Viapiana O, Bosco E, Negrelli R, Sani E, Sandri D, **Mantovani A**, Targher G, Rossini M, Gatti D. Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker. Calcif Tissue Int. 2021 Feb;108(2):231-239. doi: 10.1007/s00223-020-00768-2.
114. **Mantovani A**, Beatrice G, Stupia R, Dalbeni A. Prevalence and incidence of intra- and extrahepatic complications of NAFLD in patients with type 2 diabetes mellitus. Hepatoma Res 2020;6:78. DOI: 10.20517/2394-5079.2020.75.
115. Mezzetto L, Scorsone L, Silingardi R, Gennai S, Piffaretti G, **Mantovani A**, Bush RL, Haulon S, Veraldi GF. Bridging Stents In Fenestrated And Branched Endovascular Aneurysm Repair: A Systematic Review. Ann Vasc Surg. 2021;73:454-462. doi: 10.1016/j.avsg.2020.10.05.
116. Mariotto S, **Mantovani A**. Scientific Productivity in Neurology: Impact of the Socio-Economic Status. Neurol Sci. 2021 Apr;42(4):1563-1566. doi: 10.1007/s10072-020-04893-6. Epub 2021 Jan 2.
117. **Mantovani A**, Dalbeni A. NAFLD, MAFLD and DAFLD. Dig Liv Dis 2020; 52: 1519-1520. doi: 10.1016/j.dld.2020.09.013.
118. **Mantovani A**, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Metabolites 2021; 11: 22. <https://doi.org/10.3390/metabo11010022>.
119. Ballestri S, **Mantovani A**, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver

Disease. Diagnostics (Basel). 2021 Jan 9;11(1):E98. doi: 10.3390/diagnostics11010098.

120. Zoppini G, Bergamini C, Trombetta M, **Mantovani A**, Targher G, Toffalini A, Bittante C, Bonora E. Echocardiographic parameters according to insulin dose in young patients affected by type 1 diabetes. PLoS One. 2020 Dec 28;15(12):e0244483. doi: 10.1371/journal.pone.0244483.
121. Zusi C, Morandi A, Maguolo A, Corradi M, Costantini S, Mosca A, Crudele A, **Mantovani A**, Alisi A, Miraglia del Giudice E, Targher G, Maffei C. Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children. Nutr Metab Cardiovasc Dis 2021; 31(5): 1548-1555. doi: 10.1016/j.numecd.2021.01.020
122. **Mantovani A**, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites. 2021; 11 (2): 73. <https://doi.org/10.3390/metabo11020073>.
123. **Mantovani A**, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021; 22: 2350. <https://doi.org/10.3390/ijms22052350>.
124. **Mantovani A**, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne, Targher G. Non-alcoholic Fatty Liver Disease and Increased Risk of Incident Extra-hepatic Cancers: A Meta-Analysis of Observational Cohort Studies. Gut. 2021 Mar 8;gutjnl-2021-324191. doi: 10.1136/gutjnl-2021-324191.
125. **Mantovani A**, Valenti L. A call to action for fatty liver disease. Liver Int. 2021;41(6):1182-1185. doi: 10.1111/liv.14907.
126. **Mantovani A**, Targher G. Glucagon-like Peptide-1 Receptor Agonists For Treatment of NASH: New Insights From Subcutaneous Semaglutide. Hepatobiliary Surgery and Nutrition 2021; 10(4): 518-521. doi: 10.21037/hbsn-2021-13
127. Lonardo A, **Mantovani A**. Clearing HCV with DAAs reduces MACE in patients with prediabetes. Nutr Metab Cardiovasc Dis 2021, Jul 22;31(8):2354-2357. doi: 10.1016/j.numecd.2021.05.019.
128. **Mantovani A**. MAFLD vs NAFLD: Where are we? Dig Liv Dis 2021;53(10):1368-1372. doi: 10.1016/j.dld.2021.05.014.
129. **Mantovani A**. GLP-1 Receptor Agonists And Reduction of Liver Fat Content in NAFLD Patients: Just A Question of Weight Loss? Dig Liv Dis 2021;53(12):1673-1674. doi: 10.1016/j.dld.2021.07.013.
130. **Mantovani A**, Dalbeni A, Peserico D, Cattazzo F, Bevilacqua M, Salvagno GL, Lippi, G, Targher, G, Danese E, Fava, C. Plasma Bile Acid Profile in Patients with and without Type 2 Diabetes. Metabolites 2021, 11, 453. <https://doi.org/10.3390/metabo11070453>.
131. Targher G, **Mantovani A**, Grander C, Foco L, Motta B, Byrne CD, Pramstaller PP, Tilg H. Association between nonalcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes - The Cooperative Health Research in South Tyrol (CHRIS)-

NAFLD Substudy. *Nutr Metab Cardiovasc Dis*. 2021 Nov 29;31(12):3464-3473. doi: 10.1016/j.numecd.2021.08.037.

132. **Mantovani A**, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2021 Nov;6(11):903-913. doi: 10.1016/S2468-1253(21)00308-3.
133. **Mantovani A**, Beatrice G, Zusi C, Dalbeni A. Nonalcoholic Fatty Liver Disease on Twitter: A Sentiment Analysis. *Metab Target Organ Damage* 2021;1:6. Doi: 10.20517/mtod.2021.09.
134. **Mantovani A**, Beatrice G, Zusi C, Dalbeni A. Breastfeeding duration and reduced risk of NAFLD in midlife of parous women. *Explor Med*. 2021;2: [Online First]. <https://doi.org/10.37349/emed.2021.00056>
135. Ballestri S, **Mantovani A**, Byrne CD, Lonardo A, Targher G. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. *Metab Target Organ Damage* 2021;1:7. Doi: 10.20517/mtod.2021.05.
136. Teobaldi I, Stoico V, Perrone F, **Mantovani A**, Piccagli P, Grandi F, Baldo B. Effect of a topical gel based on Adelmidrol + Trans-traumatic acid in the treatment of diabetic foot ulcers: an open-label study. *J Am Podiatr Med Assoc*. 2021 Oct 28;20-143. doi: 10.7547/20-143.
137. **Mantovani A**, Rinaldi E, Zusi C, Beatrice G, Deganello Saccomani M, Dalbeni A. COVID-19 outbreak in children and/or adolescents. *Pediatric Research* 2022 Feb;91(3):473. doi: 10.1038/s41390-021-01787-x.
138. **Mantovani A**, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. *Gut*. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-323082.
139. Gambaro A, Lombardi G, Ribichini FL, **Mantovani A**, Bignamini AA, Gambaro G. Impact of early glomerular filtration rate decline in response to antihypertensive treatment on risk of end-stage kidney disease and cardiovascular outcomes. *J Hypertens*. 2022 Mar 1;40(3):413-421. doi: 10.1097/HJH.0000000000003066.
140. **Mantovani A**, Lombardi R, Dalbeni A. Glucose-Lowering Agents And Reduced Risk Of Incident Non-Alcoholic Fatty Liver Disease: New Insights. *HepatoBiliary Surg Nutr* 2022;11(1):156-160, doi: 10.21037/hbsn-2021-28
141. **Mantovani A**, Byrne CD, Benfari G, Bonapace S, Simon GT, Targher G. Risk of heart failure in patients with non-alcoholic fatty liver disease. *J Am Coll Cardiol*. 2022;79(2):180–191. doi: 10.1016/j.jacc.2021.11.007.
142. **Mantovani A**, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review. *Lancet Gastroenterol Hepatol*. 2022 Apr;7(4):367-378. doi: 10.1016/S2468-1253(21)00261-2
143. Bellinato F, Gisondi P, **Mantovani A**, Girolomoni G, Targher G. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. *J*

144. Fassio A, **Mantovani A**, Gatti D, Rossini M, Viapiana O, Gavioli I, Benini C, Adami G. Pharmacological treatment in adult patients with CRPS-I: A systematic review and meta-analysis of randomised controlled trials. *Rheumatology (Oxford)*. 2022 Feb 1:keac060. doi: 10.1093/rheumatology/keac060. Online ahead of print
145. **Mantovani A**, Zusi C, Lunardi G, Bonapace S, Lippi G, Maffei C, Targher G. Association Between KLF6 rs3750861 Polymorphism and Plasma Ceramide Concentrations In Post-Menopausal Women With Type 2 Diabetes. *Nutrition, Metabolism and Cardiovascular Diseases* 2022; 32: 1283-1287. Doi: 10.1016/j.numecd.2022.01.037
146. **Mantovani A**, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. *J. Clin. Med.* 2022; 11: 968. <https://doi.org/10.3390/jcm11040968>
147. **Mantovani A**, Bonapace S, Dugo C, Beatrice G, Petracca G, Cappelli D, Csermely A, Molon G, Targher G. Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure. *Int J Cardiol.* 2022 Apr 15;353:127-130. doi: 10.1016/j.ijcard.2022.02.013.
148. **Mantovani A**, Dalbeni A. Recent developments in NAFLD. *Int J Mol Sci.* 2022 Mar 7;23(5):2882. doi: 10.3390/ijms23052882.
149. Ciardullo S, **Mantovani A**, Ciaccio A, Carbone M, Invernizzi P, Perseghin GL. Hepatitis C virus infection and diabetes: a complex bidirectional relationship. *Diabetes Res Clin Pract.* 2022 May;187:109870. doi: 10.1016/j.diabres.2022.109870.
150. **Mantovani A**, Bonapace S, Targher G. Authors' reply to Zhang et al. *Int J Cardiol* 2022, Jun 1;356:105. doi: 10.1016/j.ijcard.2022.04.015
151. Lonardo A, **Mantovani A**, Petta S, Carraro A, Byrne CD, Targher G. Metabolic mechanisms underlying NAFLD or NASH re-emergence after liver transplantation. *Nat Rev Endocrinol* 2022;18:638–650. <https://doi.org/10.1038/s41574-022-00711-5>
152. **Mantovani A**, Targher G. Editorial: higher levels of certain serum bile acids in non-alcoholic fatty liver disease - new insights from Guatemala. *Aliment Pharmacol Ther.* 2022;56:357–360. DOI: 10.1111/apt.16962
153. Mosca A, **Mantovani A**, Crudele A, Panera N, Comparcola D, De Vito R, Bianchi M, Byrne CD, Targher G, Alisi A. Higher levels of plasma hyaluronic acid and N-terminal propeptide of type III procollagen are associated with lower kidney function in children with non-alcoholic fatty liver disease. *Front. Pediatr.* 2022;10:917714. doi: 10.3389/fped.2022.917714
154. **Mantovani A**, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. *Gut* 2023;72:372–380. doi:10.1136/gutjnl-2022-327672.

155. Dalbeni A, Villani R, Bevilacqua M, Sacco F, Faccincani D, Cattazzo F, Cavallone F, Mantovani A, Ceruti V, Ieluzzi D, Paon V, **Mantovani A**, Serviddio G, Sacerdoti D. Effects of Direct Acting Antiviral Agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real life Italian experience. *J Dig Dis.* 2022;23(5-6):324-330. doi: 10.1111/1751-2980.13103.
156. **Mantovani A**, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A. MAFLD And CKD: An Updated Narrative Review. *Int. J. Mol. Sci.* 2022; 23: 7007. <https://doi.org/10.3390/ijms23137007>.
157. **Mantovani A**, Csermely A, Sani E, Beatrice G, Petracca G, Lunardi G, Bonapace S, Lippi G, Targher G. Association between higher circulating leucine-rich α -2 glycoprotein 1 concentrations and specific plasma ceramides in post-menopausal women with type 2 diabetes. *Biomolecules* 2022, 12, 943. <https://doi.org/10.3390/biom12070943>.
158. **Mantovani A**, Zusi C, Csermely A, Salvagno GL, Colecchia A, Lippi G, Maffei C, Targher G. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study. *Hormones (Athens).* 2022 Sep;21(3):477-486. doi: 10.1007/s42000-022-00387-6.
159. **Mantovani A**, Csermely A, Tilg H, Byrne CD, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. *Gut* 2022, Aug 24;gutjnl-2022-328224. doi:10.1136/gutjnl-2022-328224.
160. Targher G, **Mantovani A**, Byrne CD. Glucagon-like peptide 1 receptor agonists and other incretin receptor agonists: mechanisms and possible hepatoprotective effects in non-alcoholic fatty liver disease. *Lancet Gastroenterol Hepatol* 2023; 8: 179–91. [https://doi.org/10.1016/S2468-1253\(22\)00338-7](https://doi.org/10.1016/S2468-1253(22)00338-7)
161. **Mantovani A**, Taverna A, Cappelli D, Beatrice G, Csermely A, Sani E, Byrne CD, Targher G. Long-term Adverse Effect of Liver Stiffness on Glycaemic Control in Type 2 Diabetic Patients With Non-alcoholic Fatty Liver Disease: A Pilot Study. *Int. J. Mol. Sci.* 2022, 23, 12481. <https://doi.org/10.3390/ijms232012481>.
162. Lonardo A, **Mantovani A**, Targher G, Baffy G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, clinical and research implications. *Int. J. Mol. Sci.* 2022, 23, 13320. <https://doi.org/10.3390/ijms232113320>.
163. Lonardo A, **Mantovani A**. Rewriting the natural history of MAFLD on the basis of cardiovascular risk assessment. *Nutr Metab Cardiovasc Dis.* 2023 Feb;33(2):385-387. doi: 10.1016/j.numecd.2022.12.009
164. Ravaioli F, Dajti E, **Mantovani A**, Newsome PN, Targher G, Colecchia A. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. *Gut* 2023;0:1–11. doi:10.1136/gutjnl-2022-328689.
165. **Mantovani A**, Csermely A, Taverna A, Cappelli D, Benfari G, Bonapace S, Byrne CD, Targher G. Association Between Metabolic Dysfunction-Associated

- Fatty Liver Disease and Supraventricular and Ventricular Tachyarrhythmias in Patients with Type 2 Diabetes. *Diabetes & Metabolism* 2023; 49: 101416. doi: 10.1016/j.diabet.2022.101416.
166. Ballestri S, **Mantovani A**, Di Girolamo M, Baldelli E, Capitelli M, Lonardo A. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality. *Metab Target Organ Damage* 2023;3:1. <http://dx.doi.org/10.20517/mtod.2022.23>
 167. Dei Cas A, Aldigeri R, **Mantovani A**, Masulli M, Cavalot F, Baroni MG, Cavallo G, Buzzetti R, Leonetti F, Morieri ML, Pollis RM, Targher G, Vigili de Kreutzenberg S. Sex differences in cardiovascular disease and cardiovascular risk estimation in patients with type 1 diabetes. *J Clin Endocrinol Metab.* 2023 Aug 18;108(9):e789-e798. doi: 10.1210/clinem/dgad127.
 168. **Mantovani A**, Zusi C, Csermely A, Taverna A, Cappelli D, Pagani M, Valenti L, Maffei C, Targher G. Association between PNPLA3 rs738409 variant and 5-year estimated glomerular filtration rate decline in post-menopausal women with type 2 diabetes: a panel-data analysis. *Nutr Metab Cardiovasc Dis* 2023 May;33(5):1093-1097; doi: 10.1016/j.numecd.2023.03.004
 169. **Mantovani A**, Pelusi S, Margarita S, Malvestiti F, Dell'Alma M, Bianco C, Ronzoni L, Prati D, Targher G, Valenti L. Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction. *Aliment Pharmacol Ther.* 2023 May;57(10):1093-1102. doi: 10.1111/apt.17477.
 170. **Mantovani A**, Dalbeni A. NAFLD/MAFLD: New evidence. *Int. J. Mol. Sci.* 2023, 24(8), 7241; <https://doi.org/10.3390/ijms24087241>
 171. Targher G, **Mantovani A**, Byrne CD. Reply to Dr. Chiang's comments. *Diabetes & Metabolism.* 2023, 101445.
 172. Battaglia Y, Amicone M, **Mantovani A**, Combe C, Mitra S, Basile C on behalf of EuDial Working Group of ERA. Home-based exercise in patients on maintenance dialysis: a systematic review and meta-analysis of randomized clinical trials. *Nephrol Dial Transplant.* 2023;38(11):2550-2561, <https://doi.org/10.1093/ndt/gfad102>
 173. **Mantovani A**, Csermely A, Castagna A, Antinori E, Danese E, Zusi C, Sani E, Ravaioli F, Colecchia A, Maffei C, Valenti L, Girelli D, Targher G. Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: an exploratory study. *Liver Int.* 2023 Nov;43(11):2434-2444. doi: 10.1111/liv.15649.
 174. **Mantovani A**, Morieri ML, Palmisano L, Masulli M, Cossu E, Baroni MG, Bonomo K, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Pollis RM, Aldigeri R, Dei Cas A, de Kreutzenberg S, Targher G. Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus. *Cardiovasc Diabetol.* 2023 Aug 10;22(1):204. doi: 10.1186/s12933-023-01945-x.
 175. Inciardi RM, **Mantovani A**, Targher G. Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure. *Curr Heart Fail Rep.* 2023 Aug;20(4):308-319. doi: 10.1007/s11897-023-00613-1.
 176. Csermely A, **Mantovani A**, Morieri ML, Palmisano L, Masulli M, Cossu E, Baroni MG, Bonomo K, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti

- F, Bacci S, Trevisan R, Pollis RM, Aldigeri R, Cas AD, de Kreutzenberg SV, Targher G. Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus. *Diabetes Metab.* 2023 Sep 12:101477. doi: 10.1016/j.diabet.2023.101477
177. **Mantovani A**, Tilg H, Targher G. FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomized placebo-controlled trials. *Gut.* 2023 Sep 27:gutjnl-2023-331115. doi: 10.1136/gutjnl-2023-331115.
 178. Maurelli M, Gisondi P, Bellinato F, **Mantovani A**, Targher G, Girolomoni G. Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis. *Journal of Clinical Medicine.* 2023; 12(18):6057. <https://doi.org/10.3390/jcm12186057>.
 179. Kanbay M, Basile C, Battaglia Y, **Mantovani A**, Yavuz F, Pizzarelli F, Luyckx VA, Covic A, Liakopoulos V, Mitra S. Shared decision making in patients with kidney failure. *Nephrol Dial Transplant* 2024; 39: 742–751. doi: 10.1093/ndt/gfad211.
 180. Lombardi R, **Mantovani A**, Cespiati A, Francione P, Serviddio G, Maffi G, del Zanna E, Maffei C, Colecchia A, Passigato N, Ferrarese A, Cusumano D, Villani R, Orsi E, Grancini V, Pisano G, Airaghi L, Bignamini D, Targher G, Fargion S, Fracanzani AL. Evolution of liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease in a follow-up study: possible hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors. *Dig Liver Dis* 2024;56(4):551-558. doi: 10.1016/j.dld.2023.09.023..
 181. **Mantovani A**, Csermely A, Cappelli D, Taverna A, Sani E, Shtembari E, Pagani M, Targher G. Higher circulating levels of non-esterified fatty acids are associated with faster kidney function decline in post-menopausal women with type 2 diabetes: a pilot prospective study. *Acta Diabetologica* 2024 Mar;61(3):281-288 <https://doi.org/10.1007/s00592-023-02198-6>.
 182. Souza M, Diaz I, Barchetta I, **Mantovani A**. Gastrointestinal Cancers in Lean Individuals with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Liver Int.* 2024 Jan;44(1):6-14. doi: 10.1111/liv.15763.
 183. Stupia R, Lombardi R, Cattazzo F, Zoncapè M, Mantovani A, De Marco L, **Mantovani A**, Fracanzani AL, Sacerdoti D, Dalbeni A. Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies. *J Thromb Thrombolysis.* 2024 Feb;57(2):330-336. doi: 10.1007/s11239-023-02912-9
 184. **Mantovani A**, Targher G. PNPLA3 rs738409 polymorphism and kidney dysfunction: an association beyond nonalcoholic fatty liver disease? *Metabolism and Target Organ Damage.* 2023; 3(4): 18. <http://dx.doi.org/10.20517/mtod.2023.24>
 185. Dalbeni A, Garbin M, Zoncapè M, Romeo S, Cattazzo F, Mantovani A, Cespiati A, Fracanzani AL, Tsochatzis EA, Sacerdoti D, **Mantovani A**, Lombardi R. Glomerular Hyperfiltration: a marker of fibrosis severity in Metabolic Associated Steatotic Liver Disease. *Int. J. Mol. Sci.* 2023, 24(21), 15837; <https://doi.org/10.3390/ijms242115837>.
 186. Souza M, Diaz I, Barchetta I, **Mantovani A**. Reply to Li and colleagues. *Liver Int.* 2024 Jan;44(1):265. doi: 10.1111/liv.15788
 187. Dalbeni A, Lombardi R, Henrique M, Zoncapè M, Pennisi G, Petta S, Tateishi

- R, Keklikkiran C, Colecchia A, Sacerdoti D, **Mantovani A***, Ravaioli F. Diagnostic accuracy of AGILE3+ score for the non-invasive identification of patients with non-alcoholic fatty liver disease and advanced fibrosis: a systematic review and meta-analysis. *Hepatology*. 2023 Nov 17. doi: 10.1097/HEP.0000000000000694.
188. **Mantovani A**, Morieri ML, Aldigeri R, Palmisano L, Masulli M, Bonomo K, Baroni MG, Cossu E, Cimini FA, Cavallo G, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Pollis RM, Dei Cas A, de Kreutzenberg S, Targher G. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus. *Diabetes and Metabolism* 2024; 50: 101497
 189. Dalbeni A, **Mantovani A**, Lombardi R, Ravaioli F. Reply: Diagnostic accuracy of AGILE3+ score for the non-invasive identification of patients with non-alcoholic fatty liver disease and advanced fibrosis: a systematic review and meta-analysis. *Hepatology*. 2024 May 1;79(5):E146-E147..
 190. Bilson J, **Mantovani A***, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. *Diabetes & Metabolism* 50 (2024) 101506; <https://doi.org/10.1016/j.diabet.2023.101506>.
 191. Battaglia Y, **Mantovani A***, Shroff R, Alfano G, Meijers B, Franssen C, Combe Cand Basile C on behalf of the EuDial Working Group of the European Renal Association. Online haemodiafiltration and all-cause mortality: how fragile are the results of the studies published so far? *Nephrol Dial Transplant*, 2024, 39, 1034–1036. doi: 10.1093/ndt/gfae003.
 192. Lonardo A, Ballestri S, **Mantovani A***, Targher G, Bril F. Endpoints in NASH clinical trials – are we blind in one eye? *Metabolites* 2024,14,40. <https://doi.org/10.3390/metabo14010040>
 193. Mezzetto L, Mastrorilli D, Zanetti E, Scoccia E, Pecoraro B, Sboarina A, **Mantovani A**, Veraldi GF. Clinical risk factors and features on computed tomography angiography in high-risk carotid artery plaque in patients with type 2 diabetes. *Int Angiol*. 2024 Mar 12. doi: 10.23736/S0392-9590.24.05154-X.
 194. Lombardi R, Dalbeni A, **Mantovani A**, Ravaioli F. Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with non alcoholic fatty liver disease. *Hepatology*. 2024;79:E155–E156. DOI:10.1097/HEP.0000000000000775
 195. Ciardullo S, **Mantovani A**. Resmetirom for the treatment of nonalcoholic steatohepatitis: evaluating the robustness of available evidence. *Dig Liver Dis*. 2024 Mar 29:S1590-8658(24)00310-4. doi: 10.1016/j.dld.2024.03.009.
 196. Ciardullo S, **Mantovani A**, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. *Liver Int*. 2024;44:1762-1767. doi: 10.1111/liv.15939
 197. **Mantovani A**, Csermely A, Bilson J, Borella N, Scoccia E, Pecoraro B, Shtembari E, Morandin R, Polyzos SA, Valenti L, Tilg H, Byrne CD, Targher G. Association Between Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Updated Meta-Analysis. *Gut* 2024;73:1554–1561. doi: 10.1136/gutjnl-2024-332491.
 198. **Mantovani A**, Targher G. PNPLA3 variation and kidney disease. *Liver Int*. 2025 Mar;45(3):e16010. doi: 10.1111/liv.16010

199. Pugliese N, Polverini D, Lombardi R, Pennisi G, Ravaioli F, Armandi A, Buzzetti E, Dalbeni A, Liguori A, **Mantovani A**, Villani R, Gardini I, Hassan C, Valenti L, Miele L, Petta S, Sebastiani G, Aghemo A. Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness. *J Pers Med*. 2024 May 26;14(6):568. doi: 10.3390/jpm14060568.
200. **Mantovani A**, Morandin R, Fiorio V, Lando MG, Petta S, Ferraro PM, Targher G. Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis. *Intern Emerg Med*. 2024 Jul 11. doi: 10.1007/s11739-024-03705-5.
201. Pennisi G, Infantino G, Celsa C, Di Maria G, Enea M, Vaccaro M, Cannella R, Cicioli C, La Mantia C, **Mantovani A**, Mercurio F, Tilg H, Targher G, Di Marco V, Cammà C, Petta S. Clinical outcomes of MAFLD versus NAFLD: A Meta-analysis of Observational Studies. *Liver Int*. 2024 Aug 19. doi: 10.1111/liv.16075.
202. **Mantovani A**, Busti F, Borella N, Scoccia E, Pecoraro B, Sani E, Morandin R, Csermely A, Piasentin D, Grespan E, Castagna A, Bilson J, Byrne CD, Valenti L, Girelli D, Targher G. Elevated plasma hepcidin concentrations are associated with an increased risk of mortality and nonfatal cardiovascular events in patients with type 2 diabetes: a prospective study. *Cardiovasc Diabetol* 23, 305 (2024). <https://doi.org/10.1186/s12933-024-02377-x>
203. **Mantovani A**, Morandin R, Fiorio V, Lando MG, Gaviraghi A, Motta L, Gobbi F, Tilg H, Byrne CD, Targher G Association Between MASLD and Increased Risk of Serious Bacterial Infections Requiring Hospital Admission: A Meta-Analysis. *Liver Int*. 2025; 45:e16101. doi:10.1111/liv.16101.
204. **Mantovani A**, Molinero AE, Bonapace S, Lunardi G, Salgarello M, Morandin R, Moretta F, Conti A, Molon G, Laaksonen R, Byrne CD, Targher G. Basal and post-stress ceramide-based risk score CERT1 predicts all-cause mortality and nonfatal myocardial infarction in patients with suspected or established coronary artery disease undergoing stress myocardial perfusion scintigraphy. *Nutr Metab Cardiovasc Dis* 2025 Feb;35(2):103735. doi: 10.1016/j.numecd.2024.09.005.
205. Maffei C, Morandi A, Zusi C, Olivieri F, Fornari E, Cavarzere P, Piona C, Corradi M, Emiliani F, Da Ros A, Berni Canani R, **Mantovani A**, Targher G. Hepatic lipogenesis marked by GCKR-modulated triglycerides increases serum FGF21 in children/teens with obesity. *Diabetes Obes Metab*. 2025 Feb;27(2):825-834. doi: 10.1111/dom.16081.
206. Bonapace S, **Mantovani A**. Do Sex and Gender-Related Differences Account to Different Risk of Developing Heart Failure in Middle-Aged People with Metabolic Syndrome? *Metabolites* 2024 Sep 30;14(10):528. doi: 10.3390/metabo14100528.
207. Bilson J, Hydes TJ, McDonnell D, Buchanan RM, Scorletti E, **Mantovani A**, Targher G, Byrne CD. Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study. *Liver Int* 2025; 45: e16159. doi: 10.1111/liv.16159.
208. Targher G, **Mantovani A**, Byrne CD, Tilg H. Recent Advances in Incretin-Based Therapy for MASLD: From Single to Dual or Triple Incretin Receptor Agonists. *Gut* 2025;74:487-497. doi: 10.1136/gutjnl-2024-334023.
209. **Mantovani A**, Targher G. Response Letter: Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: It's

early days. Liver International 2025; 45: e16194.
<https://doi.org/10.1111/liv.16194>

210. **Mantovani A**, Morandin R, Sani E, Fiorio V, Shtembari E, Bonapace S, Petta S, Polyzos SP, Byrne CD, Targher G. MASLD is associated with an increased long-term risk of atrial fibrillation: an updated systematic review and meta-analysis. *Liver Int.* 2025 Jan;45(1):e16128. doi: 10.1111/liv.16218.
211. Souza M, Al-Sharif L, Khalil SM, Villela-Nogueira CA, **Mantovani A**. Global epidemiology and characteristics of MASLD in type 1 diabetes: an updated systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2024 Dec 11:S1542-3565(24)01066-8. doi: 10.1016/j.cgh.2024.09.038
212. **Mantovani A**, Lunardi G, Bonapace S, Molinero AE, Morandin R, Fiorio V, Molon G, Byrne CD, Targher G. Ceramide-based risk score CERT-1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study. *Diabetes Obes Metab.* 2025 Mar;27(3):1488-1497. doi: 10.1111/dom.16156.
213. Souza M, Al-Sharif L, Diaz I, **Mantovani A***, Villela-Nogueira CA. Global epidemiology and implications of PNPLA3 I148M variant in MASLD: a systematic review and meta-analysis. *J Clin Exp Hepatol.* 2025 May-Jun;15(3):102495. doi: 10.1016/j.jceh.2024.102495
214. Lonardo A, Stefan N, **Mantovani A**. Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer. *Trends in Endocrinology & Metabolism* 2025 Jan 9:S1043-2760(24)00331-X. doi: 10.1016/j.tem.2024.12.009.
215. Souza M, Al-Sharif L, Diaz I, Khalil SM, Lv X-H, **Mantovani A***, Villela-Nogueira CA. Representation of sex, race and ethnicity in MASH randomized controlled trials: a systematic review and meta-analysis. *Liver International*, 2025; 45:e70029
216. Battaglia Y, Shroff R, Meijers B, Nistor I, Alfano G, Franssen C, Luyckx V, Liakopoulos V, **Mantovani A**, Baciga F, Caccia F, Momentè C, Davenport A, Blankestijn PJ, Covic A, Combe C, Basile C. Haemodiafiltration versus high-flux haemodialysis - a Consensus Statement from the EuDial Working Group of the ERA. *Nephrol Dial Transplant.* 2025 Feb 6:gfaf024. doi: 10.1093/ndt/gfaf024.
217. Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Infantino G, Di Maria G, Pinato DJ, Cabibbo G, Enea M, **Mantovani A**, Tilg H, Targher G, Cammà C, Petta S. Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies. *Gut.* 2025 Feb 27:gutjnl-2024-334591. doi: 10.1136/gutjnl-2024-334591.
218. Vergani M, Borella ND, Rizzo M, Rizzo M, Conti M, Perra S, Bianconi E, Sani E, Csermely A, Grespan E, Targher G, Perseghin G, **Mantovani A***, Ciardullo S. Metabolic dysfunction-associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi-centre cross-sectional study. *Diabetes Obes Metab.* 2025; 1-11. doi: 10.1111/dom.16333
219. Fassio A, Berti A, **Mantovani A**, Adami G, Pollastri F, Gatti D, Bixio R, Messina V, Rossini M, Bertelle D, Bertoldo E, Galvagni I, Bortolotti R, Viapiana O. Osteoporosis and fractures in systemic vasculitides: a systematic review and meta-analysis. *Front. Immunol.* 2025; 16:1545546. doi:

220. **Mantovani A**, Morandin R, Lando MG, Fiorio V, Pennisi G, Petta S, Stefan N, Tilg H, Byrne CD, Targher G. Sodium-Glucose Cotransporter-2 Inhibitor Use and Risk of Liver-Related Events in Patients with Type 2 Diabetes: A Meta-Analysis of Observational Cohort Studies. *Diabetes Care* 2025 Jun 1;48(6):1042-1052. doi: 10.2337/dc25-0282.
221. Marinelli A, Konstantinos Trachanas K, Corso M, Fasoli D, Canton M, Costa A, Cecchini F, Bonapace S, **Mantovani A**, Bonocore M, Mignano A, Cicerone C, Molon G. An alternative method for phrenic nerve monitoring during cryoballoon procedures. *Heart Rhythm* 2025 Mar 30;6(6):739-744. doi: 10.1016/j.hrro.2025.03.016.
222. Souza M, **Mantovani A**, Villela-Nogueira CA. Response Letter: Bridging Gaps in Demographic Equity: Towards Inclusive Representation in MASH Randomised Trials. *Liver Int.* 2025 Jun;45(6):e70137. doi: 10.1111/liv.70137.
223. Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, **Mantovani A**, Targher G, Krag A, Rinella ME, Cammà C, Petta S. Hepatic and Extrahepatic Outcomes in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease versus Metabolic Dysfunction and Alcohol-Related Steatotic Liver Disease (MetALD): A Meta-Analysis. *Lancet Gastroenterology and hepatology*, 2015, in press
224. Zerbinati L, Caccia F, Baciga F, Belvedere Murri M, Esposito P, Caruso R, Nistor I, Meijers B, Basile C, Combe C, Grassi L, **Mantovani A**, Battaglia Y; EuDial Working Group of ERA. Suicide risk in patients undergoing hemodialysis: a systematic review and meta-analysis of prevalence. *Ren Fail.* 2025 Dec;47(1):2521453. doi: 10.1080/0886022X.2025.2521453.
225. Jamalnia M, Zare F, **Mantovani A**, Targher G, Lonardo A. Metabolic Dysfunction-Associated Steatotic Liver Disease and Sex-Specific Risk of Fatal and Non-Fatal Cardiovascular Events: A Meta-analysis. *Diabetes Obes Metab.* 2025 Sep;27(9):5171-5181. doi: 10.1111/dom.16568.
226. **Mantovani A**, Bonapace S, Morandin R, Sani E, Lunardi G, Salgarello M, Molon G, Targher G. A new plasma ceramide 24-based risk score predicts overall mortality and nonfatal myocardial infarction in patients with suspected or known coronary artery disease. *Nutr Metab Cardiovasc Dis.* 2025 Jun 21:104206. doi: 10.1016/j.numecd.2025.104206.
227. **Mantovani A**, Ciardullo S, Sani E, Csermely A, Shtembari E, Milani I, Sbraccia P, Perseghin G, Leonetti F, Targher G, Guglielmi V, Capoccia D. Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study. *Diabetes Metab.* 2025 Sep;51(5):101684. doi: 10.1016/j.diabet.2025.101684.
228. **Mantovani A**, Morandin R, Fiorio V, Lando MG, Stefan N, Tilg H, Byrne CD, Targher G. Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials. *Liver Int.* 2025 Sep;45(9):e70256. doi: 10.1111/liv.70256.

Other publications:

1. **Mantovani A**, Targher G. Rassegna: Diabete e NAFLD, *Il Diabete*, dicembre 2014.
2. **Mantovani A**, Targher G. Rassegna: Associazione tra iperuricemia e IRC, *Medico e Paziente*, 2013.
3. **Mantovani A**, Zoppini G, Targher G. Rassegna: Diabete mellito e complicanze epatiche: epidemiologia, diagnosi e trattamento, *Medico e Paziente*, 2015.
4. **Mantovani A**, Fossa I, Rigolon R, Zoppini G, Targher G. Caso clinico: setticemia con ascessi epatici multipli da streptococco constellatus: un grande mimo. *Il Diabete*, Maggio 2016, Vol 28.
5. Chapter "Accoglimento in reparto della persona con diabete: ruolo del medico" of the book "La gestione della persona con diabete ricoverata per altra patologia" editor by SID.
6. Chapter 16 "Diabetes and NAFLD" per il libro "Diabetes Complications, Comorbidities and Related Disorders" editor by Springer.
7. **Mantovani A**, Targher G. Tessuto Adiposo e Rischio Cardiovascolare. *Giornale Italiano dell'Arteriosclerosi* 2017; 8 (3): 3-21.
8. <http://www.ricercamix.org/2019/02/13/comPLICANZE-micro-e-macro-vascolari-nel-diabete-mellito/>
9. <http://www.ricercamix.org/2019/05/08/la-mortalita-in-un-soggetto-afetto-da-diabete/>
10. Chapter 8: "NAFLD, Diabetes, and Other Endocrine Diseases: Clinical Implications" per il libro "Non-alcoholic fatty liver disease: A 360 degree overview" editor by Springer
11. **Mantovani A**. Rassegna: Ruolo dei farmaci antidiabetici nel trattamento della NAFLD, *Il Diabete*, luglio 2021.
12. Toffalini A, **Mantovani A**, Zoppini G. Rassegna: La terapia insulinica nel diabete mellito di tipo 2, *Il Diabete*, 2022

SCIENTIFIC AWARDS

- Award SISA Scipione Martini Prize 2013 for best oral communication
- Award SISA Scipione Martini Prize 2016 for best oral communication
- Award SID Premio di Mario 2017 for the best work published in (2016)
- Award Scipione Martini SISA 2017 for best oral communication
- Award Poster SIE 2017 for best poster communication
- Award Parma Diabete 2017 (XI edizione)
- Award AMD-SID Triveneto 2017 for best oral communication
- Award SISA Scipione Martini Prize 2017 for best oral communication
- Award SISA Scipione Martini Prize 2018 for best oral communication
- Award SISA Scipione Martini Prize 2019 for best oral communication
- Award SISA Scipione Martini Prize 2022 for best oral communication
- First Prize Winner 2022 Best Papers of Metabolism and Target Organ Damage

PARTICIPATION IN RESEARCH GROUPS, SCIENTIFIC CONSORTIA, RESEARCH OR PROFESSIONAL ASSOCIATIONS, SCIENTIFIC COMMITTEES

1. Active participation in the research group directed by Prof. Targher, whose main research lines are as follows:
 - (a) role of MAFLD/NAFLD in the development of cardiovascular complications in patients with type 2 or in those with type 1 diabetes mellitus;
 - (b) role of MAFLD/NAFLD in the development of chronic kidney disease in patients with type 2 diabetes mellitus or in those with type 1 diabetes mellitus;
 - (c) role of vitamin D in the development of micro- and macrovascular complications in patients with diabetes mellitus;

- (d) role of uric acid in the development of micro- and macrovascular complications in patients with diabetes mellitus;
 - (e) role of plasma ceramides in the development of cardiovascular complications in patients with and without diabetes mellitus;
 - (f) role of *PNPLA3* rs738409 and *TM6SF* rs58542926 polymorphisms in the development of NAFLD and extra-hepatic complications;
2. Affiliated for more than 5 years with the following scientific societies: Italian Diabetes Society (SID), Italian Endocrinology Society (SIE), Italian Association for the Study of the Liver (AISF), Italian Society for the Study of Atherosclerosis (SISA);
 3. Member of the Scientific Commission of the Italian Diabetes Society (SID) from 2018 to 2022;
 4. Participation in the drafting and publication of the SISA Updates from 2019;
 5. Supervisor/Co-supervisor of the following theses of the Degree in Nursing from 2019:
 - (a) DIETARY AND THERAPEUTIC ADJUSTMENTS FOR THE PREVENTION OF HYPOGLYCEMIA IN ATHLETES WITH TYPE 1 DIABETES MELLITUS
 - (b) HISTORY OF TYPE 1 DIABETES FROM TRADITIONAL THERAPY TO THE USE OF THE MICROINFUSER
 6. Supervisor/Co-supervisor of the following theses of the Degree in Medicine and Surgery from 2017:
 - (a) "Increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes mellitus and asymptomatic hyperuricemia";
 - (b) "Relationship between non-alcoholic fatty liver disease (NAFLD), bone damage and serum markers of bone turnover in patients with type 2 diabetes mellitus";
 - (c) "Association between plasma ceramides and severity of coronary stenosis in patients with high cardiovascular risk";
 - (d) "Prevalence of hepatic fibrosis (measured by Fibroscan) and its possible association with diabetic nephropathy in an outpatient sample of patients with type 2 diabetes";
 7. Supervisor/Co-supervisor of the following Specialization theses in Endocrinology and Metabolic Diseases from 2019:
 - (a) NAFLD AND HEPATIC FIBROSIS IN OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS: RELATION TO CHRONIC VASCULAR AND KIDNEY COMPLICATIONS
 - (b) ASSOCIAZIONE TRA RIDOTTI LIVELLI CIRCOLANTI DI ADIPONECTINA E PRESENZA/SEVERITÀ DELLA STEATOSI EPATICA NON ALCOLICA (NAFLD) IN PAZIENTI AFFETTI DA DIABETE MELLITO TIPO 2
 8. He acts since 2017 as reviewer for various international scientific journals in his specific disciplinary sector, including BMJ, Lancet GH, APT, Diabetic Medicine, NMCD, Metabolism, Diabetes & Metabolism, Liver International, Dig Liv Dis, Diabetes Care;
 9. He acts as Academic Editor for J Clin Transl Hepatol since 2018.
 10. He acts on the Editorial Board of the Exploration of Medicine magazine since 2019
 11. He acts from 2020 on the Editorial Board of Liver International magazine
 12. He acts from 2020 on the Editorial Board of Digestive Liver Disease magazine
 13. He acts from 2020 on the Editorial Board of the magazine Hepatoma Research
 14. He acts from 2020 on the Editorial Board of the journal Nutrition, Metabolism and Cardiovascular Diseases (NMCD)
 15. He acts from 2022 as Associate Editor for the journal Nutrition, Metabolism and Cardiovascular Diseases (NMCD)
 16. He was among the world's top 100,000 scientists based on standardized citability indicators in 2020 (Ioannidis JPA, Boyack KW, Baas J (2020) Updated science-wide author databases of standardized citation indicators. PLoS Biol 18 (10): e3000918. <https://doi.org/10.1371/journal.pbio.3000918>)
 17. He was among the world's top 100,000 scientists based on standardized citability indicators in 2022 (<https://doi.org/10.17632/btchxktzyw.4>)
 18. He is among the first researchers in the world in the field of NAFLD/MAFLD in 2022 (<https://expertscape.com/ex/non-alcoholic+fatty+liver+disease>)

19. Guest Editor for the International Journal of Molecular Sciences for the Special Issue "Nonalcoholic Fatty Liver Disease / Metabolic Associated Fatty Liver Disease: New Insights" in 2020-2021 (https://www.mdpi.com/journal/ijms/special_issues/MAFLD_2021).

20. He acts as Guest Editor for the International Journal of Molecular Sciences for the Special Issue "Nonalcoholic Fatty Liver Disease / Metabolic Associated Fatty Liver Disease: New Insights 2.0" in 2021-2022 (https://www.mdpi.com/journal/ijms/special_issues/Fatty_Liver2)

INVITED SPEAKERS

Title	Meeting	Year	County
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) E COMPLICANZE CARDIOVASCOLARI NEL DIABETE	PARMA DIABETE 2017 – XI Edizione	2017	Italy
LECTIO MAGISTRALIS: NAFLD AND CARDIOVASCULAR DISEASE: NOT ONLY A MATTER OF ATHEROSCLEROSIS	XI REUNION DIABETES Y OBESIDAS, MALAGA, 2017	2017	Spain
NAFLD AND CARDIOVASCULAR DISEASE	XXVIII CONGRESO DE LA SOCIEDAD CASTELLANO LEONESA DE ENDOCRINOLOGÍA, DIABETES Y NUTRICIÓN, SEGOVIA, 2017	2017	Spain
NAFLD, CORONARIE ED ALTRO	TRENTENNALE DELLE SCUOLE DI SPECIALIZZAZIONE IN ENDOCRINOLOGIA, DIABETOLOGIA E MALATTIE DEL METABOLISMO	2017	Italy
TERAPIA ANTIBIOTICA DI I, II E III LIVELLO	LA GESTIONE DEL PAZIENTE CON LESIONI AL PIEDE DURANTE IL RICOVERO E DOPO LA DIMISSIONE	2018	Italy
IMPATTO DEGLI INIBITORI DI SGLT-2 NEI PAZIENTI CON DIABETE TIPO 2	CORSO RESIDENZIALE SID, ROMA 2018	2018	Italy
CROSS-TALK HEART-LIVER: NAFLD E RISCHIO CARDIOVASCOLARE	SPRING MEETING DEI GRUPPI GIOVANI RICERCATORI DI SIIA-SIMI-SISA, RIMINI 2019	2019	Italy
DANNO EPATICO NEL DIABETE: È POSSIBILE CONTRASTARLO?	PANORAMA DIABETE, RICCIONE 2019	2019	Italy
DIABETE, PREVENZIONE SECONDARIA	CORTONA INSPIRES THE FUTURE	2019	Italy
STORIA NATURALE DELLA NAFLD: LEZIONE DALL'EPIDEMIOLOGIA	28° CONGRESSO SID NAZIONALE	2020	Italy
I "NUOVI" NEMICI NAFLD E OBESITÀ MORBIGENA, NELLA PREVENZIONE CARDIOVASCOLARE DEL PAZIENTE DIABETICO DI RECENTE DIAGNOSI: MARKERS DI RISCHIO E BERSAGLI TERAPEUTICI	METACUORE 2021 (WEBINAR)	2021	Italy
MEDICAZIONI AVANZATE	CORSO RESIDENZIALE "DIABETE OGGI"	2021	Italy
A 10 ANNI DAL PRIMO STUDIO DI SICUREZZA CARDIOVASCOLARE PER I NUOVI FARMACI IPOGLICEMIZZANTI NEL DM2: RCT O REAL WORLD	1 ^a ACCADEMIA DIABETOLOGICA TRIVENETO	2021	Italy

EVIDENCE?			
FARMACI ANTIDIABETECI E DANNO EPATICO	PANORAMA DIABETE, RICCIONE 2021	2021	Italy
IL RISCHIO CARDIOVASCOLARE DEL PAZIENTE CON DMT2: DALLE EVIDENZE ALLE NUOVE LINEE GUIDA ITALIANE	Diab&More 2022, VERONA 2022	2022	Italy
TRAPIANTI E NUOVE TERAPIE DIABETOLOGICHE	SIE TRIVENETO 2022, PADOVA	2022	Italy
DISLIPIDEMIE MISTE: UN MONDO VARIEGATO	SISA TRIVENETO 2022, TRENTO	2022	Italy
DIABETE, OSSO E VITAMINA D	SUONIAMO LE TRE NOTE, VERONA	2022	Italy
FEGATO GRASSO E INFIAMMATO: CAUSA O EFFETTO?	40 ANNI DELLA SCUOLA ENDOCRINO-METABOLICA DI VERONA	2022	Italy
NAFLD: CAUSA E CONSEGUENZA DEL DIABETE MELLITO TIPO 2	29° CONGRESSO NAZIONALE SID	2022	Italy
ESAMI STRUMENTALI: QUALI E QUANDO?	LA MALATTIA EPATICA NELL'AMBULATORIO DI MALATTIE METABOLICHE E... VICEVERSA	2023	Italy
GLP-1RAs e NAFLD/NASH	SPRING MEETING 2023	2023	Italy
IL DIABETE E IL TRAPIANTO: RUOLO DELLE NUOVE TERAPIE NEL PAZIENTE TRAPIANTATO	IL TRAPIANTO DI RENE: UNA PERFETTA SINERGIA TRA NEFROLOGO E CHIRURGO	2023	Italy
STUDIO METABOLICO E INDICAZIONI ALLA FARMACOTERAPIA	CORSO OBESITA' AOVR 2023	2023	Italy
LA FISIOPATOLOGIA DELLA NAFLD	PANORAMA DIABETE 2023	2023	Italy

INVITED POSTERS

TITLE	MEETING	YEAR	COUNTRY
LA SCLEROSI VALVOLARE AORTICA (AVS) E LE CALCIFICAZIONI DELL'ANELLO MITRALICO (MAC) SI ASSOCIANO AD AUMENTATA MORTALITÀ IN DIABETICI TIPO 2	CONGRESSO NAZIONALE SID, TORINO 2012	2012	Italy
LA STEATOSI EPATICA NON ALCOLICA SI ASSOCIA AD UN'AUMENTATA PREVALENZA DI FIBRILLAZIONE ATRIALE IN PAZIENTI AFFETTI DA DIABETE MELLITO TIPO 2	CONGRESSO NAZIONALE SIE, PADOVA 2013	2013	Italy
DISFUNZIONE DIASTOLICA VENTRICOLARE IN PAZIENTI CON DIABETE TIPO 2 E STEATOSI EPATICA NON ALCOLICA (NAFLD).	CONGRESSO NAZIONALE SID, BOLOGNA 2014	2014	Italy
NONALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH HEART VALVE CALCIFICATION IN TYPE 2 DIABETES.	AMERICAN DIABETES ASSOCIATION'S SCIENTIFIC SESSIONS MEETING, BOSTON 2015	2015	USA
HEART VALVE CALCIFICATION IN PATIENTS WITH TYPE 2 DIABETES AND NONALCOHOLIC FATTY LIVER DISEASE	CONGRESSO NAZIONALE SIE, TAORMINA 2015	2015	Italy
NONALCOHOLIC FATTY LIVER DISEASE IS INDEPENDENTLY ASSOCIATED WITH EARLY	CONGRESSO NAZIONALE SIE, TAORMINA 2015	2015	Italy

LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES			
NON-ALCOHOLIC FATTY LIVER DISEASE IS INDEPENDENTLY ASSOCIATED WITH EARLY LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES	CONGRESSO AISF, MODENA 2015	2015	Italy
LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN TYPE 2 DIABETIC PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE	CONGRESSO EAIC, SIVIGLIA 2015	2015	Spain
ASSOCIAZIONE TRA INSUFFICIENZA MITRALICA ED AUMENTATA MORTALITA' TOTALE E CARDIOVASCOLARE IN UNA COORTE DI PAZIENTI CON DIABETE TIPO 2	CONGRESSO NAZIONALE SID, MAGGIO 2016.	2016	Italy
PIEDE DIABETICO COMPLICATO DA SPONDILODISCITE CON RACCOLTA PARAVERTEBRALE ED ENDOCANALARE: A CASE REPORT	CONGRESSO NAZIONALE SID, MAGGIO 2016	2016	Italy
FOOT COMPLICATED BY VERTEBRAL OSTEOMYELITIS AND EPIDURAL ABSCESS: A CASE REPORT	WUWHS 2016	2016	Italy
NONALCOHOLIC FATTY LIVER DISEASE IS INDEPENDENTLY ASSOCIATED WITH AN INCREASED RISK OF HEART BLOCK IN HOSPITALIZED PATIENTS WITH TYPE 2 DIABETES	AMERICAN DIABETES ASSOCIATION'S SCIENTIFIC SESSIONS MEETING, SAN DIEGO (USA) 2017.	2017	USA
NONALCOHOLIC FATTY LIVER DISEASE IS INDEPENDENTLY ASSOCIATED WITH AN INCREASED RISK OF HEART BLOCK IN HOSPITALIZED PATIENTS WITH TYPE 2 DIABETES	CONGRESSO SIE NAZIONALE, ROMA 2017	2017	Italy
ASSOCIATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND BONE MINERAL DENSITY IN CHILDREN OR ADOLESCENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS	CONGRESSO SIE NAZIONALE, ROMA 2019	2019	Italy
NAFLD E FIBROSI EPATICA IN PAZIENTI AMBULATORIALI CON DIABETE MELLITO TIPO 2: RELAZIONE CON LE COMPLICANZE CRONICHE VASCOLARI E RENALI	28° CONGRESSO SID NAZIONALE	2020	Italy
ASSOCIAZIONE TRA LIVELLI CIRCOLANTI DI CERAMIDI E CKD IN PAZIENTI CON DIABETE MELLITO TIPO 2	28° CONGRESSO SID NAZIONALE	2020	Italy
CERAMIDES AND RISK OF MAJOR CARDIOVASCULAR EVENTS: A META-ANALYSIS OF LONGITUDINAL STUDIES	28° CONGRESSO SID NAZIONALE	2020	Italy
ASSOCIAZIONE TRA RIDOTTI LIVELLI CIRCOLANTI DI ADIPONECTINA E PRESENZA/SEVERITÀ DI NAFLD IN PAZIENTI AFFETTI DA DIABETE MELLITO TIPO 2	SISA TRIVENETO 2022, TRENTO	2022	Italy

ASSOCIAZIONE TRA RIDOTTI LIVELLI CIRCOLANTI DI ADIPONECTINA E PRESENZA/SEVERITÀ DI NAFLD IN PAZIENTI AFFETTI DA DIABETE MELLITO TIPO 2	29° CONGRESSO NAZIONALE SID	2022	Italy

INVITED ORAL COMMUNICATIONS

TITLE	MEETING	YEAR	COUNTRY
LA SCLEROSI VALVOLARE DELL'AORTA E LE CALCIFICAZIONI DELL'ANELLO MITRALICO SI ASSOCIANO AD AUMENTATA MORTALITÀ CARDIOVASCOLARE E TOTALE IN DIABETICI TIPO 2	GRUPPO DI STUDIO "DIABETE ED ATEROSCLEROSI", PADOVA, FEBBRAIO 2012	2012	Italy
ASSOCIAZIONE EPATOPATIA STEATOSICA NON ALCOLICA (NAFLD) E FIBRILLAZIONE ATRIALE IN PAZIENTI AFFETTI DA DIABETE TIPO 2	CONGRESSO SID-AMD TRIVENETO, PADOVA, NOVEMBRE 2012.	2012	Italy
EPATOPATIA STEATOSICA NON ALCOLICA ED AUMENTATA INCIDENZA DI INSUFFICIENZA RENALE CRONICA IN PAZIENTI CON DIABETE TIPO 1	CONGRESSO SID-AMD TRIVENETO, PADOVA, NOVEMBRE 2013.	2013	Italy
ALTERAZIONI ECOCARDIOGRAFICHE IN PAZIENTI CON DIABETE TIPO 2 E STEATOSI EPATICA NON ALCOLICA	CONGRESSO SID-AMD TRIVENETO, VERONA, NOVEMBRE 2014	2014	Italy
ASSOCIAZIONE TRA STEATOSI EPATICA NON ALCOLICA (NAFLD) E SCLEROSI VALVOLARE AORTICA IN PAZIENTI CON DIABETE TIPO 2	CONGRESSO NAZIONALE SID, BOLOGNA 2014.	2014	Italy
NONALCOHOLIC FATTY LIVER DISEASE IS INDEPENDENTLY ASSOCIATED WITH EARLY LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES	CONGRESSO NAZIONALE SIE, TAORMINA 2015	2015	Italy
ASSOCIAZIONE TRA IPERURICEMIA ED AUMENTATA PREVALENZA DI FIBRILLAZIONE ATRIALE IN PAZIENTI OSPEDALIZZATI CON DIABETE MELLITO TIPO 2	CONGRESSO SID-AMD TRIVENETO, TRENTO, NOVEMBRE 2015.	2015	Italy
AUMENTATA PREVALENZA DI ARITMIE VENTRICOLARI IN PAZIENTI CON DIABETE TIPO 2 E STEATOSI EPATICA NON ALCOLICA (NAFLD).	GRUPPO DI STUDIO "DIABETE ED ATEROSCLEROSI", BOLOGNA, MARZO 2016.	2016	Italy
LA STEATOSI EPATICA NON ALCOLICA SI ASSOCIA AD AUMENTATA PREVALENZA DI TACHIARITMIE VENTRICOLARI IN PAZIENTI CON DIABETE TIPO 2.	CONGRESSO SISA TRIVENETO, PADOVA, MAGGIO 2016.	2016	Italy
LA STEATOSI EPATICA NON ALCOLICA (NAFLD) SI ASSOCIA AD AUMENTATA PREVALENZA DI TACHIARITMIE VENTRICOLARI IN PAZIENTI CON DIABETE MELLITO TIPO 2	CONGRESSO NAZIONALE SID, MAGGIO 2016	2016	Italy
ACCESSO IN PRONTO	CONGRESSO SID-AMD	2016	Italy

SOCCORSO PER IPOGLICEMIA SEVERA IN PAZIENTI CON DIABETE MELLITO NOTO: DATI DI UNO STUDIO MULTICENTRICO ITALIANO	TRIVENETO, TREVISO 2016.		
ASSOCIAZIONE TRA STEATOSI EPATICA NON ALCOLICA (NAFLD) ED INCIDENZA DI MALATTIA CARDIOVASCOLARE IN PAZIENTI CON DIABETE TIPO 1	CONGRESSO SID-AMD TRIVENETO, TREVISO 2016.	2016	Italy
LA STEATOSI EPATICA NON ALCOLICA SI ASSOCIA AD UN'AUMENTATA PREVALENZA DI BLOCCHI CARDIACI NEI PAZIENTI OSPEDALIZZATI AFFETTI DA DIABETE MELLITO TIPO 2	GRUPPO DI STUDIO ATEROSCLEROSI SID, BOLOGNA 2017	2017	Italy
LA STEATOSI EPATICA NON ALCOLICA SI ASSOCIA AD UN AUMENTATO RISCHIO DI POLINEUROPATIA SIMMETRICA DISTALE IN PAZIENTI AMBULATORIALI ADULTI AFFETTI DA DIABETE TIPO 1.	GRUPPO DI STUDIO ATEROSCLEROSI SID, BOLOGNA 2017	2017	Italy
L'IPERURICEMIA ASINTOMATICA SI ASSOCIA AD UN AUMENTATO RISCHIO DI FIBRILLAZIONE ATRIALE PAROSSISTICA IN PAZIENTI AMBULATORIALI AFFETTI DA DIABETE TIPO 2	GRUPPO DI STUDIO ATEROSCLEROSI SID, BOLOGNA 2017	2017	Italy
NONALCOHOLIC FATTY LIVER DISEASE IS INDEPENDENTLY ASSOCIATED WITH AN INCREASED RISK OF HEART BLOCK IN HOSPITALIZED PATIENTS WITH TYPE 2 DIABETES	CONGRESSO SISA TRIVENETO, PADOVA 2017.	2017	Italy
RELAZIONE TRA STEATOSI EPATICA NON ALCOLICA (NAFLD), DANNO OSSEO E MARKERS SIERICI DI TURNOVER OSSEO IN DONNE AFFETTE DA DIABETE MELLITO TIPO 2	CONGRESSO SID-AMD TRIVENETO, PADOVA 2018.	2018	Italy
ASSOCIATION BETWEEN PLASMA CERAMIDE CONCENTRATIONS AND INDUCIBLE MYOCARDIAL ISCHEMIA IN PATIENTS WITH ESTABLISHED OR SUSPECTED CORONARY ARTERY DISEASE REFERRED FOR CLINICALLY INDICATED STRESS MYOCARDIAL PERFUSION SCINTIGRAPHY	CONGRESSO SISA TRIVENETO, PADOVA 2018	2018	Italy
ASSOCIATIONS BETWEEN HIGHER PLASMA CERAMIDE LEVELS AND LOWER PERCENTAGE OF POST-STRESS MYOCARDIAL PERFUSION IN PATIENTS WITH ESTABLISHED OR SUSPECTED CORONARY ARTERY DISEASE UNDERGOING MYOCARDIAL PERFUSION SCINTIGRAPHY	CONGRESSO NAZIONALE SISA, ROMA 2018	2018	Italy
ASSOCIATION BETWEEN PLASMA CERAMIDE CONCENTRATIONS AND INDUCIBLE MYOCARDIAL ISCHEMIA IN PATIENTS WITH ESTABLISHED OR	GRUPPO DI STUDIO ATEROSCLEROSI SID, BOLOGNA 2018	2018	Italy

SUSPECTED CORONARY ARTERY DISEASE REFERRED FOR CLINICALLY INDICATED STRESS MYOCARDIAL PERFUSION SCINTIGRAPHY			
ASSOCIATION BETWEEN PLASMA CERAMIDE CONCENTRATIONS AND INDUCIBLE MYOCARDIAL ISCHEMIA IN PATIENTS WITH ESTABLISHED OR SUSPECTED CORONARY ARTERY DISEASE REFERRED FOR CLINICALLY INDICATED STRESS MYOCARDIAL PERFUSION SCINTIGRAPHY	CONGRESSO SIE TRIVENETO 2018	2018	Italy
ASSOCIATION BETWEEN PLASMA CERAMIDES AND SEVERITY OF CORONARY-ARTERY STENOSIS IN PATIENTS WITH CLINICAL INDICATIONS FOR CORONARY ANGIOGRAPHY	CONGRESSO SISA TRIVENETO, PADOVA 2019	2019	Italy
ASSOCIATION BETWEEN HIGHER LEVELS OF DISTINCT PLASMA CERAMIDES AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE: RESULTS FROM A SUBSET ANALYSIS OF THE GISSI-HF TRIAL	CONGRESSO SISA NAZIONALE, ROMA 2019	2019	Italy
ASSOCIATION BETWEEN HIGHER LEVELS OF DISTINCT PLASMA CERAMIDES AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE: RESULTS FROM A SUBSET ANALYSIS OF THE GISSI-HF TRIAL	GDS SID-SISA SULL'ATEROSCLEROSI	2020	Italy
ASSOCIAZIONE TRA PNPLA3 rs738409 ED AUMENTATO RISCHIO DI MALATTIA RENALE CRONICA (CKD) IN PAZIENTI CON DIABETE TIPO 2 E NAFLD	28° CONGRESSO NAZIONALE SID	2020	Italy
ASSOCIAZIONE TRA RIDOTTI LIVELLI CIRCOLANTI DI ADIPONECTINA E PRESENZA/SEVERITÀ DI NAFLD IN PAZIENTI AFFETTI DA DIABETE MELLITO TIPO 2	SISA TRIVENETO 2022, TRENTO	2022	Italy
DIABETE, OSSO E VITAMINA D	SUONIAMO LE TRE NOTE, VERONA	2022	Italy
FEGATO GRASSO E INFIAMMATO: CAUSA O EFFETTO?	40 ANNI DELLA SCUOLA ENDOCRINO-METABOLICA DI VERONA	2022	Italy
NAFLD: CAUSA E CONSEGUENZA DEL DIABETE MELLITO TIPO 2	29° CONGRESSO NAZIONALE SID	2022	Italy
PROSPETTIVE TERAPEUTICHE NELLA NAFLD: TRA VECCHIO E NUOVO, COSA FUNZIONA?	36 CONGRESSO NAZIONALE SISA	2022	Italy
ESAMI STRUMENTALI: QUALI E QUANDO?	LA MALATTIA EPATICA NELL'AMBULATORIO DI MALATTIE METABOLICHE E...VICEVERSA	2023	Italy
GLP-1RAs e NAFLD/NASH	SPRING MEETING 2023	2023	Italy
IL DIABETE E IL TRAPIANTO: RUOLO DELLE NUOVE TERAPIE NEL PAZIENTE TRAPIANTATO	IL TRAPIANTO DI RENE:	2023	Italy

TECHNICAL SKILLS
AND COMPETENCES

- Good knowledge of the following softwares:
 - WORD,
 - POWERPOINT,
 - EXCEL,
 - SPSS v21,
 - MYSTAR,
 - STATPLUS,
 - iWORK,
 - PAGES,
 - NUMBERS,
 - KEYNOTE,
 - STATA v16.1,
 - PROMETA3,
 - REVMANAGER 5.4

Date 09 September 2025

Prof. Alessandro Mantovani

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV.

